The development of inhibitory antibodies to therapeutic factor VIII (FVIII) in up to 40% of people with severe hemophilia A (HA) is the major complication in treatment/prevention of hemorrhages. The reasons some people with HA develop inhibitors while others do not, remain unclear.
In this session from the WFH 2020 Virtual Summit, Sebastien Lacroix-Desmazes, Kathleen Pratt and Valder Arruder summarize our understanding of anti-FVIII immune responses, the roles of T cells, both effector and regulatory, and generally discuss the interplay between FVIII and the immune system, both in the case of replacement therapy and in gene therapy.
Click on the icon below to access more on-demand Virtual Summit recordings.
This WFH webinar was originally presented in English.